3 news items
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
CNTB
22 May 24
and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
CNTB
7 May 24
industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
CNTB
16 Apr 24
with the goal
- Prev
- 1
- Next